Navigation Links
BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
Date:2/7/2008

SAN ANTONIO, Feb. 7 /PRNewswire/ -- BioNumerik Pharmaceuticals, Inc. today announced treatment of the first patient in a global Phase III clinical trial of BioNumerik's anticancer drug candidate known as Karenitecin(R) in advanced ovarian cancer patients. BioNumerik is developing Karenitecin (also known as BNP1350) as an investigational new anti-tumor drug in the camptothecin class of chemotherapy drugs. Based on prior studies, BioNumerik believes Karenitecin has the potential for fewer side-effects, better efficacy, and less susceptibility to drug resistance mechanisms compared to the currently marketed camptothecin drugs.

The Phase III trial has been designed as a global, randomized, multi-center open label trial to prospectively evaluate the safety and efficacy of Karenitecin compared to the chemotherapy drug topotecan (also known as Hycamtin(R)). Either Karenitecin or topotecan will be given intravenously daily for 5 consecutive days repeated every 3 weeks to advanced ovarian cancer patients who have previously been treated with platinum and taxane chemotherapy drugs but have become resistant to the platinum/taxane therapy. BioNumerik has received written agreement from the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) regarding the clinical trial design and protocol.

Four Phase II clinical trials of intravenously administered Karenitecin have been completed in the U.S. in patients with advanced ovarian cancer, metastatic malignant melanoma, advanced non-small cell lung cancer, and primary brain tumors. BioNumerik has also initiated a Phase I clinical trial to evaluate the safety and effectiveness of an orally administered Karenitecin formulation. Based on prior studies, BioNumerik believes Karenitecin may have the following potential advantages over currently marketed camptothecins:
-- Comparable or improved effectiveness in the treatment of certain

cancers, with a potentially improved safety profile and fewer of the

dose-limiting side-effects caused by camptothecin drugs including:

- lower incidence of severe diarrhea than that caused by irinotecan

(also known as Camptosar(R));

- lower incidence of anemia and neutropenia (reduction in white blood

cell counts), than that caused by topotecan (also known as

Hycamtin(R));

-- Less susceptibility than currently marketed camptothecins to common

drug resistance mechanisms found in many types of human cancer cells,

including resistance mechanisms that are specific to the camptothecin

class; and

-- Because Karenitecin is lipophilic (fat loving), BioNumerik believes

Karenitecin may have enhanced tissue penetration, drug delivery and

bioavailability compared to existing water soluble camptothecins.

In commenting on these developments, Frederick H. Hausheer, M.D., BioNumerik's Chairman & Chief Executive Officer stated: "There is a large unmet need for 2nd and 3rd -line therapies that can prevent progression of recurrent or progressive ovarian cancer with reduced risk of cumulative toxicity in patients who have become resistant to platinum/taxane-based chemotherapy. Ovarian cancer is difficult to diagnose early and patients are usually diagnosed with advanced disease (Stage III or IV). Outcomes for patients with advanced ovarian cancer remain poor. Up to 80% of ovarian cancer patients who initially respond to treatment will ultimately relapse and require additional therapy, and treatment options for patients with advanced recurrent ovarian cancer are limited. In addition, all approved agents for the treatment of advanced ovarian cancer are associated with significant toxicity that can be dose-limiting."

Dr. Hausheer added, "We believe the safety and efficacy outcomes from the previously completed Karenitecin Phase II advanced ovarian cancer trial compare favorably with the historically reported results of approved agents. Based on the Phase II outcomes and our pre-clinical data, we are pursuing Karenitecin Phase III testing in advanced ovarian cancer patients who have become resistant to platinum/taxane chemotherapy."

About BioNumerik:

BioNumerik Pharmaceuticals, Inc., based in San Antonio, Texas, is focused on the discovery, development and commercialization of novel drugs for the treatment of cancer and cancer supportive care. The Company currently has two drug candidates, Karenitecin(R) and Tavocept(TM), in late-stage clinical development. BioNumerik has eight additional drug discovery research programs, and has generated a patent portfolio of more than 450 patents and pending patent applications worldwide.

Editor's Note: This release is also available on the Internet at: http://www.bionumerik.com

Contact:

David R. Margrave

BioNumerik Pharmaceuticals, Inc.

(210) 614-1701

email: david.margrave@bnpi.com


'/>"/>
SOURCE BioNumerik Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
4. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
7. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
8. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
9. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
10. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
11. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... February 22, 2017 The ... market are Olympus Corporation, Nikon Corporation, and Leica ... 75% in the overall market in 2015. The ... innovation through result-oriented research and development activities and ... to focus on expanding their business to emerging ...
(Date:2/22/2017)... 22, 2017 According to a new market ... SIMS, CUSCO), Application (Laparoscopy, Colposcopy, Hysteroscopy, D&C, Ablation, Biopsy), & End ... published by MarketsandMarkets, the global market is expected to reach USD ... a CAGR of 7.1% during the forecast period. ... ...
(Date:2/22/2017)... Fla. , Feb. 22, 2017  Corin Group ... System, a device used to treat patients with both ... of shoulder arthritis. The condition, known as cuff tear ... and shoulder. The Humelock Reversed Shoulder ... upper extremities technology company based near Lyon, ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... 22, 2017 , ... In a recent article ... context (age, illness and life choices) should be dissociated from medical errors and ... In addition, all too often, studies regarding health system performance in other countries, ...
(Date:2/22/2017)... - NORTHERN CALIFORNIA (PRWEB) , ... February 22, ... ... to expand the pipeline and the number of African American/Black students who want ... students and residents to pursue their careers as physicians in the Oakland/San Francisco ...
(Date:2/21/2017)... ... February 21, 2017 , ... Tripp Lite, a world-leading ... extension cords that meet the most current standards. , The adoption by the ... National Fire Protection Association (NFPA) 101 – Life Safety Code (LSC) and NFPA ...
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... As recently ... States according to the American Society of Plastic Surgeons. Some patients want to make ... functionality of their nose and improve their breathing ability. The team at usrhinoplasty.org ...
(Date:2/21/2017)... ... , ... Support of value-based care models requires collaboration across all facets of ... solutions, Fogo Data Centers announces the launch of the Fogo Partner Community™. , At ... in which all systems work well, work together, and work together well. In ...
Breaking Medicine News(10 mins):